As the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization, AnaptysBio is focused on the generation of antibody therapeutics. Founded in 2005, AnaptysBio is a privately-held company that has established broad intellectual property directed to the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders and antibody-drug conjugate applications.